New pharmaceuticals approved by FDA in 2020: Small-molecule drugs derived from amino acids and related compounds
| Autor: | Hidenori Abe, Kunisuke Izawa, Arina Nakano, Hiroki Moriwaki, Aiyao Liu, Jianlin Han, Vadim A. Soloshonok, Hiroyuki Konno |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Peptidomimetic
Pharmacology Catalysis Analytical Chemistry chemistry.chemical_compound Drug Discovery medicine Amisulpride Lonafarnib Amino Acids Drug Approval Spectroscopy Setmelanotide Molecular Structure Chemistry United States Food and Drug Administration Organic Chemistry medicine.disease Small molecule United States Rimegepant Overactive bladder Pharmaceutical Preparations Drug delivery medicine.drug |
| Zdroj: | ChiralityREFERENCES. 34(1) |
| ISSN: | 1520-636X |
| Popis: | Amino acids (AAs) play an important role in the modern health industry as key synthetic precursors for pharmaceuticals, biomaterials, biosensors, and drug delivery systems. Currently, over 30% of small-molecule drugs contain residues of tailor-made AAs or derived from them amino-alcohols and di-amines. In this review article, we profile 12 AA-derived new pharmaceuticals approved by the FDA in 2020. These newly introduced drugs include Tazverik (epithelioid sarcoma), Gemtesa (overactive bladder), Zeposia (multiple sclerosis), Byfavo (induction and maintenance of procedural sedation), Cu 64 dotatate, and Gallium 68 PSMA-11 (both PET imaging), Rimegepant (acute migraine), Zepzelca (lung cancer), Remdesivir (COVID-19), Amisulpride (nausea and vomiting), Setmelanotide (obesity), and Lonafarnib (progeria syndrome). For each compound, we describe the spectrum of biological activity, medicinal chemistry discovery, and synthetic preparation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text